Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
ConditionSLE
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
This is a case-control study investigating serum IL-33 levels and their association with clinical manifestations in systemic lupus erythematosus (SLE). The study compares IL-33 levels in three groups: SLE patients with lupus nephritis, SLE patients without nephritis, and healthy controls. The goal is to clarify IL-33's role as a biomarker reflecting disease activity and organ involvement, especially renal pathology.
Eligibility criteria
Qualifiers
Adults aged 18 years and older.
Diagnosed with systemic lupus erythematosus according to the American College of Rheumatology (ACR) criteria.
For the lupus nephritis group: confirmed diagnosis of lupus nephritis based on clinical, laboratory, and renal biopsy findings.
For the control group: healthy individuals matched for age and sex, with no history of autoimmune or renal diseases.
Disqualifiers
Patients with other autoimmune diseases. Patients with chronic infections or malignancies. Pregnant or lactating women. Patients with end-stage renal disease (ESRD) or on dialysis. Individuals who refuse to provide informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
150 Participants
are grouped into 3 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov